These findings show that PEDF decreased pro-metastatic biomarker expression under post-menopausal conditions in ER+/HER2- BC cells; with PEDF-mediated p-NFκB-p65, TNFα, CXCR4, and uPAR downregulation specific to post-menopausal conditions. This evidence concerns the gene ERBB2 and breast cancer.